

20 December 2022

Cizzle Biotechnology Holdings plc

("Cizzle" or the "Company")

Update re. timing of Admission

Cizzle Biotechnology Holdings plc, the UK based diagnostics developer, announces that further to the announcement made by the Company on 19 December 2022, the Company has become aware that the next available listing hearing date for the Admission of the shares pursuant to the Subscription is 4 January 2023. It is now therefore expected that Admission will become effective at 8.00 a.m. on 5 January 2023.

Words defined in this announcement shall have the same meaning as in the announcement released on 19 December 2022.

Enquiries:

Cizzle Biotechnology Holdings plc
Allan Syms (Executive Chairman)

Via IFC Advisory

Allenby Capital Limited
John Depasquale
Alex Brearley

+44(0) 20 3328 5656

Novum Securities Limited
Colin Rowbury
Jon Bellis

+44(0) 20 7399 9400

IFC Advisory Limited
Tim Metcalfe
Florence Chandler

+44(0) 20 3934 6630

About Cizzle Biotechnology

Cizzle Biotechnology is also developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. For more information, please see <https://cizzlebiotechnology.com> You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.